HALO logo
halo search icon
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
VNDA · NAS

Vanda Pharmaceuticals Inc.

US$6.18

Price Arrow0.19 (3.17%)
20/05/2026 04:00:01 PM
All-CompaniesAll-ConsensusEMA 125 BreakdownHALO AllHALO Consensus Value
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Vanda Pharmaceuticals Inc. Overview

VNDA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Neutral

Earnings

Weak

Growth

Earnings

Neutral

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About VNDA

icon

Telephone

1.202.734.3400

icon

Address

Suite 300 E, 2200 Pennsylvania Avenue NW, Washington, DC 20037

Description

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

VNDA Price Chart

Key Stats

Market Cap

US$360.21M

PE

29.40

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 4.14 - 9.94

Trade Value (12mth)

US$2,314,059.00

1 week

-4.62%

1 month

-11.65%

YTD

-27.39%

1 year

38.66%

All time high

33.44

Key Fundamentals

EPS 3 yr Growth

-3467.50%

EBITDA Margin

-64.40%

Operating Cashflow

-$109m

Free Cash Flow Return

-24.80%

ROIC

-50.10%

Interest Coverage

0.00

Quick Ratio

2.40

Other Data

Shares Outstanding (Fully Diluted)

59m

HALO Sector

Healthcare

Next Company Report Date

10-Feb-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

VNDA Announcements

Latest Announcements

DateAnnouncements
07 May 26
07 May 26
07 May 26
07 May 26
23 April 26

VNDA Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock0.04-0.32-3.74locklocklock
EPS (Fully Diluted)
$locklocklocklock0.04-0.32-3.74locklocklock
Growth
%locklocklocklock-60.7-843.7-1,051.2locklocklock
PE
Xlocklocklocklock96.839129.4locklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Vanda Pharmaceuticals Inc. (VNDA:NAS)?
Halo FAQ
The current share price of Vanda Pharmaceuticals Inc. (VNDA:NAS) is USD$6.18.
What is the 52-week high share price for Vanda Pharmaceuticals Inc. (VNDA:NAS)?
Halo FAQ
The 52-week high share price for Vanda Pharmaceuticals Inc. (VNDA:NAS) is USD$9.94.
What is the 52-week low share price for Vanda Pharmaceuticals Inc. (VNDA:NAS)?
Halo FAQ
The 52-week low share price for Vanda Pharmaceuticals Inc. (VNDA:NAS) is USD$4.14.
What is the dividend yield for Vanda Pharmaceuticals Inc. (VNDA:NAS)?
Halo FAQ
Vanda Pharmaceuticals Inc. (VNDA:NAS) does not pay a dividend.
What was Vanda Pharmaceuticals Inc. (VNDA:NAS) last dividend payment?
Halo FAQ
Vanda Pharmaceuticals Inc. (VNDA:NAS) does not pay a dividend.
What is the franking level for Vanda Pharmaceuticals Inc. (VNDA:NAS)?
Halo FAQ
Vanda Pharmaceuticals Inc. (VNDA:NAS) has a franking level of 0.00%.
In which sector is Vanda Pharmaceuticals Inc. (VNDA:NAS) classified?
Halo FAQ
Vanda Pharmaceuticals Inc. (VNDA:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for Vanda Pharmaceuticals Inc. (VNDA:NAS)?
Halo FAQ
The current P/E ratio for Vanda Pharmaceuticals Inc. (VNDA:NAS) is 29.40.

See beyond the curve.

One solution for research, investing and portfolio management.